All In Biotech

Drug Trial Radar · NCT07500506

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A FIFTH DOSE OF 6-VALENT OSPA-BASED LYME DISEASE VACCINE, VLA15, IN HEALTHY PARTICIPANTS ≥7 YEARS OF AGE

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,712 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,712

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

Dec 4, 2026

Study completion Dec 4, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Mar 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 7 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and older, * have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners. * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater). The study will compare the experiences of people receiving the study vaccine or saltwater shot. Participants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.

Conditions

  • Lyme Disease

Interventions

  • VLA15Biological

    VLA15 injection IM

  • PlaceboBiological

    Saline Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting prespecified local reactionsTime frame: Within 7 days following each study intervention administration
  2. Percentage of participants reporting prespecified systemic eventsTime frame: Within 7 days following each study intervention administration
  3. Percentage of participants reporting adverse events (AEs)Time frame: Through 1 month following study intervention administration
  4. Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)Time frame: Through study completion, up to approximately 12 months.
  5. Percentage of participants reporting serious adverse events (SAEs)Time frame: Through study completion, up to approximately 12 months.
  6. Geometric mean ratio (GMR) of anti-OspA IgG concentrations for each serotype (ST1-ST6)Time frame: At 1 month after completion of Dose 5
  7. Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6).Time frame: At 1 month after completion of Dose 5

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Northern Light Eastern Maine Medical Center

    Bangor, Maine · Not yet recruiting

  • Northern Light Family Medicine and Residency Center

    Bangor, Maine · Not yet recruiting

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Recruiting

  • Hunterdon Medical Center

    Flemington, New Jersey · Not yet recruiting

  • Smith Allergy and Asthma Specialists

    Cortland, New York · Recruiting

  • Smith Allergy & Asthma Specialists

    Horseheads, New York · Recruiting

  • Altoona Center For Clinical Research

    Duncansville, Pennsylvania · Recruiting

  • Allegheny Health and Wellness Pavilion

    Erie, Pennsylvania · Recruiting

  • Central Erie Primary Care

    Erie, Pennsylvania · Recruiting

  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

    Pittsburgh, Pennsylvania · Recruiting

  • Preferred Primary Care Physicians, Preferred Clinical Research - St.Clair

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Robert Packer Hospital

    Sayre, Pennsylvania · Recruiting

  • Frontier Clinical Research, LLC

    Scottdale, Pennsylvania · Recruiting

  • Northeast Clinical Trials Group

    Scranton, Pennsylvania · Recruiting

  • Frontier Clinical Research, LLC

    Smithfield, Pennsylvania · Recruiting

  • Preferred Primary Care Physicians

    Uniontown, Pennsylvania · Not yet recruiting

  • Velocity Clinical Research, Providence

    East Greenwich, Rhode Island · Not yet recruiting

  • The University of Vermont Medical Center Inc.

    Burlington, Vermont · Not yet recruiting

  • Amherst Family Practice, P.C.

    Winchester, Virginia · Not yet recruiting

  • Milestone Research Inc.

    London, Ontario, Canada · Not yet recruiting

  • Stouffville Medical Research Institute Inc.

    Stouffville, Ontario, Canada · Not yet recruiting

  • Diex Recherche Inc. Division Sherbrooke

    Sherbrooke, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.